Compare New York Times Co (NYT) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
New York Times Co vs BIO-TECHNE Corp — how do they compare? New York Times Co trades at $75.56 (market cap $12.29B), while BIO-TECHNE Corp trades at $71.63 (market cap $11.16B). The key difference: New York Times Co and BIO-TECHNE Corp are close in size by market cap, and New York Times Co pays the higher dividend (1.21%). Which is the better fit depends on your goals.
| NYT | TECH | |
|---|---|---|
Market Cap | $12.29B | $11.16B |
Sector | Media | Health |
52-Week High | $85.86 | $72.12 |
52-Week Low | $51.43 | $43.31 |
Enterprise Value | $11.68B | $11.24B |
Dividend Yield | 1.21% | 0.45% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
